<p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）的股票在週六發佈給客户和投資者的研究報告中被 Weiss Ratings 的分析師重申了 “賣出（d-）” 評級，Weiss Ratings 報道。</p>
<p>獲取 <strong>Protara Therapeutics</strong> 的提醒：</p>
<h2>Protara Therapeutics 價格表現</h2>
<p>週五，TARA 股票交易下跌 0.06 美元，達到 5.10 美元。該公司的交易量為 409,192 股，而其平均交易量為 561,198 股。Protara Therapeutics 的 52 周低點為 1.96 美元，52 周高點為 10.48 美元。該公司的市值為 1.9677 億美元，市盈率為-3.15，貝塔值為 1.53。該業務的 50 日移動平均線為 4.00 美元，200 日移動平均線為 3.55 美元。</p>
<p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）最後一次發佈季度財報是在 8 月 11 日，週一。該公司報告每股收益（EPS）為-0.35 美元，超出分析師一致預期的-0.43 美元，超出幅度為 0.08 美元。研究分析師預計 Protara Therapeutics 在當前年度的每股收益將為-3.32 美元。</p>
<h2>機構投資者對 Protara Therapeutics 的看法</h2>
<p>一些機構投資者最近對 TARA 的持倉進行了調整。新澤西州警察和消防員退休系統在第二季度購買了 Protara Therapeutics 的新股份，價值約 30,000 美元。Quadrature Capital Ltd 在第二季度購買了 Protara Therapeutics 的新股份，價值約 35,000 美元。摩根大通在第二季度購買了 Protara Therapeutics 的新股份，價值約 46,000 美元。洛杉磯資本管理公司在第二季度購買了 Protara Therapeutics 的新股份，價值約 47,000 美元。最後，Intech Investment Management LLC 在第二季度購買了 Protara Therapeutics 的新股份，價值約 49,000 美元。對沖基金和其他機構投資者持有該公司 38.13% 的股票。</p>
<h2>Protara Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Protara Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於推進用於治療癌症和罕見疾病的變革性療法。該公司的主導項目是 TARA-002，一種正在進行的細胞治療，目前處於針對非肌肉侵襲性膀胱癌和淋巴畸形的二期臨牀試驗中。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票比 Protara Therapeutics 更好</li>
<li>什麼是財報？</li>
<li>Tractor Supply 股票看起來像是一個買入並持有的贏家</li>
<li>如何使用股票篩選器尋找股票</li>
<li>3 只遠低於 52 周高點的股票有望在第四季度反彈</li>
<li>投資優先股與普通股的比較</li>
<li>大銀行在財報季節開始時設定基調</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Protara Therapeutics 嗎？</h2>
<p>在你考慮 Protara Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Protara Therapeutics 並不在名單上。</p>
<p>雖然 Protara Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TARA

<p>Weiss Ratings 已重新確認 Protara Therapeutics (NASDAQ:TARA) 的 “賣出 (D-)” 評級。該股票交易價格下跌至 $5.10，52 周範圍為 $1.96 至 $10.48。Protara 報告的季度每股收益為 ($0.35)，超過了 ($0.43) 的預期。機構投資者持有該公司 38.13% 的股份，該公司專注於癌症和罕見疾病的治療，其主要項目正在進行膀胱癌的二期臨牀試驗</p>

<p>Protara Therapeutics (NASDAQ:TARA - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）的股票在週六發佈給客户和投資者的研究報告中被 Weiss Ratings 的分析師重申了 “賣出（d-）” 評級，Weiss Ratings 報道。</p>
</div><p>Get <strong>Protara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Protara Therapeutics</strong> 的提醒：</p>
</div><h2>Protara Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Protara Therapeutics 價格表現</h2>
</div><p>TARA stock traded down $0.06 during trading on Friday, reaching $5.10. The company had a trading volume of 409,192 shares, compared to its average volume of 561,198. Protara Therapeutics has a 52 week low of $1.96 and a 52 week high of $10.48. The company has a market cap of $196.77 million, a P/E ratio of -3.15 and a beta of 1.53. The business has a 50 day moving average of $4.00 and a 200 day moving average of $3.55.</p>
<div class="lb-trans"><p>週五，TARA 股票交易下跌 0.06 美元，達到 5.10 美元。該公司的交易量為 409,192 股，而其平均交易量為 561,198 股。Protara Therapeutics 的 52 周低點為 1.96 美元，52 周高點為 10.48 美元。該公司的市值為 1.9677 億美元，市盈率為-3.15，貝塔值為 1.53。該業務的 50 日移動平均線為 4.00 美元，200 日移動平均線為 3.55 美元。</p>
</div><p>Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Research analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protara Therapeutics（納斯達克代碼：TARA - 獲取免費報告）最後一次發佈季度財報是在 8 月 11 日，週一。該公司報告每股收益（EPS）為-0.35 美元，超出分析師一致預期的-0.43 美元，超出幅度為 0.08 美元。研究分析師預計 Protara Therapeutics 在當前年度的每股收益將為-3.32 美元。</p>
</div><h2>Institutional Investors Weigh In On Protara Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Protara Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in TARA. Police &amp; Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $30,000. Quadrature Capital Ltd purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $35,000. JPMorgan Chase &amp; Co. purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $47,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 38.13% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近對 TARA 的持倉進行了調整。新澤西州警察和消防員退休系統在第二季度購買了 Protara Therapeutics 的新股份，價值約 30,000 美元。Quadrature Capital Ltd 在第二季度購買了 Protara Therapeutics 的新股份，價值約 35,000 美元。摩根大通在第二季度購買了 Protara Therapeutics 的新股份，價值約 46,000 美元。洛杉磯資本管理公司在第二季度購買了 Protara Therapeutics 的新股份，價值約 47,000 美元。最後，Intech Investment Management LLC 在第二季度購買了 Protara Therapeutics 的新股份，價值約 49,000 美元。對沖基金和其他機構投資者持有該公司 38.13% 的股票。</p>
</div><h2>Protara Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Protara Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於推進用於治療癌症和罕見疾病的變革性療法。該公司的主導項目是 TARA-002，一種正在進行的細胞治療，目前處於針對非肌肉侵襲性膀胱癌和淋巴畸形的二期臨牀試驗中。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Protara Therapeutics</li>
<li>What Are Earnings Reports?</li>
<li>Tractor Supply Stock Looks Like a Buy-and-Hold Winner</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Big Banks Are Setting the Tone as Earnings Season Kicks Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Protara Therapeutics 更好</li>
<li>什麼是財報？</li>
<li>Tractor Supply 股票看起來像是一個買入並持有的贏家</li>
<li>如何使用股票篩選器尋找股票</li>
<li>3 只遠低於 52 周高點的股票有望在第四季度反彈</li>
<li>投資優先股與普通股的比較</li>
<li>大銀行在財報季節開始時設定基調</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TARA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Protara Therapeutics 嗎？</h2>
</div><p>Before you consider Protara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Protara Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Protara Therapeutics 並不在名單上。</p>
</div><p>While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Protara Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Protara Therapeutics（納斯達克股票代碼：TARA）在 Weiss Ratings 被評為賣出（D-）評級